"Penicillanic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A building block of penicillin, devoid of significant antibacterial activity. (From Merck Index, 11th ed)
| Descriptor ID |
D010397
|
| MeSH Number(s) |
D02.065.589.099.750.687 D02.886.108.750.687 D03.633.100.300.750.687
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Penicillanic Acid".
Below are MeSH descriptors whose meaning is more specific than "Penicillanic Acid".
This graph shows the total number of publications written about "Penicillanic Acid" by people in this website by year, and whether "Penicillanic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Penicillanic Acid" by people in Profiles.
-
Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial. JAMA. 2023 05 09; 329(18):1579-1588.
-
Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. J Antimicrob Chemother. 2020 05 01; 75(5):1228-1236.
-
Characteristics and Outcomes of Complicated Intra-abdominal Infections Involving Pseudomonas aeruginosa from a Randomized, Double-Blind, Phase 3 Ceftolozane-Tazobactam Study. Antimicrob Agents Chemother. 2016 07; 60(7):4387-90.
-
Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016 05 18; 8(339):339ra71.
-
Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam. Surg Infect (Larchmt). 2012 Feb; 13(1):38-42.
-
Prior antimicrobial exposure and the risk for bloodstream infection with fluconazole-non-susceptible Candida strains. Scand J Infect Dis. 2010 Jul; 42(6-7):506-9.
-
Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. Clin Microbiol Infect. 2008 Jan; 14 Suppl 1:181-4.
-
Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006 Jun; 50(6):2244-7.
-
Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 2005 Nov; 49(11):4555-60.
-
Chromophoric spin-labeled beta-lactam antibiotics for ENDOR structural characterization of reaction intermediates of class A and class C beta-lactamases. Spectrochim Acta A Mol Biomol Spectrosc. 2004 May; 60(6):1279-89.